18 results on '"Verbeek, Marcel M."'
Search Results
2. Temporal Ordering of Biomarkers in Dutch-Type Hereditary Cerebral Amyloid Angiopathy
- Author
-
Koemans, Emma A., Rasing, Ingeborg, Voigt, Sabine, van Harten, Thijs W., van der Zwet, Reinier G.J., Kaushik, Kanishk, Schipper, Manon R., van der Weerd, Nelleke, van Zwet, Erik W., van Etten, Ellis S., van Osch, Matthias J.P., Kuiperij, Bea, Verbeek, Marcel M., Terwindt, Gisela M., Greenberg, Steven M., van Walderveen, Marianne A.A., and Wermer, Marieke J.H.
- Published
- 2024
- Full Text
- View/download PDF
3. An attenuated, adult case of AADC deficiency demonstrated by protein characterization
- Author
-
Bisello, Giovanni, primary, Saris, Christiaan G.J., additional, Franchini, Rossella, additional, Verbeek, Marcel M., additional, Willemsen, Michel A.A.P., additional, Perduca, Massimiliano, additional, and Bertoldi, Mariarita, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
- Author
-
Vervuurt, Marc, primary, Kuiperij, H. Bea, additional, de Kort, Anna M., additional, Kersten, Iris, additional, Klijn, Catharina J. M., additional, Schreuder, Floris H. B. M., additional, and Verbeek, Marcel M., additional
- Published
- 2024
- Full Text
- View/download PDF
5. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy
- Author
-
Rasing, Ingeborg, primary, Voigt, Sabine, additional, Koemans, Emma A., additional, de Kort, Anna M., additional, van Harten, Thijs W., additional, van Etten, Ellis S., additional, van Zwet, Erik W., additional, Stoops, Erik, additional, Francois, Cindy, additional, Kuiperij, Bea H., additional, Klijn, Catharina J.M., additional, Schreuder, Floris H.B.M., additional, van der Weerd, Louise, additional, van Osch, Matthias J.P., additional, van Walderveen, Marianne A.A., additional, Verbeek, Marcel M., additional, Terwindt, Gisela M., additional, and Wermer, Marieke J.H., additional
- Published
- 2024
- Full Text
- View/download PDF
6. Divergent Associations of Slow‐Wave Sleep versus Rapid Eye Movement Sleep with Plasma Amyloid‐Beta
- Author
-
Rosenblum, Yevgenia, primary, Pereira, Mariana, additional, Stange, Oliver, additional, Weber, Frederik D., additional, Bovy, Leonore, additional, Tzioridou, Sofia, additional, Lancini, Elisa, additional, Neville, David A., additional, Klein, Nadja, additional, de Wolff, Timo, additional, Stritzke, Mandy, additional, Kersten, Iris, additional, Uhr, Manfred, additional, Claassen, Jurgen A. H. R., additional, Steiger, Axel, additional, Verbeek, Marcel M., additional, and Dresler, Martin, additional
- Published
- 2024
- Full Text
- View/download PDF
7. Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy.
- Author
-
van den Berg, Emma, Kersten, Iris, Brinkmalm, Gunnar, Johansson, Kjell, de Kort, Anna M., Klijn, Catharina J. M., Schreuder, Floris H. B. M., Gobom, Johan, Stoops, Erik, Portelius, Erik, Gkanatsiou, Eleni, Zetterberg, Henrik, Blennow, Kaj, Kuiperij, H. Bea, and Verbeek, Marcel M.
- Subjects
CEREBRAL amyloid angiopathy ,LIQUID chromatography-mass spectrometry ,PEPTIDES ,ALZHEIMER'S disease ,BIOMARKERS - Abstract
Brain amyloid‐β (Aβ) deposits are key pathological hallmarks of both cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD). Microvascular deposits in CAA mainly consist of the Aβ40 peptide, whereas Aβ42 is the predominant variant in parenchymal plaques in AD. The relevance in pathogenesis and diagnostic accuracy of various other Aβ isoforms in CAA remain understudied. We aimed to investigate the biomarker potential of various Aβ isoforms in cerebrospinal fluid (CSF) to differentiate CAA from AD pathology. We included 25 patients with probable CAA, 50 subjects with a CSF profile indicative of AD pathology (AD‐like), and 23 age‐ and sex‐matched controls. CSF levels of Aβ1‐34, Aβ1‐37, Aβ1‐38, Aβ1‐39, Aβ1‐40, and Aβ1‐42 were quantified by liquid chromatography mass spectrometry. Lower CSF levels of all six Aβ peptides were observed in CAA patients compared with controls (p = 0.0005–0.03). Except for Aβ1‐42 (p = 1.0), all peptides were decreased in CAA compared with AD‐like subjects (p = 0.007–0.03). Besides Aβ1‐42, none of the Aβ peptides were decreased in AD‐like subjects compared with controls. All Aβ peptides combined differentiated CAA from AD‐like subjects better (area under the curve [AUC] 0.84) than individual peptide levels (AUC 0.51–0.75). Without Aβ1‐42 in the model (since decreased Aβ1‐42 served as AD‐like selection criterion), the AUC was 0.78 for distinguishing CAA from AD‐like subjects. CAA patients and AD‐like subjects showed distinct disease‐specific CSF Aβ profiles. Peptides shorter than Aβ1‐42 were decreased in CAA patients, but not AD‐like subjects, which could suggest different pathological mechanisms between vascular and parenchymal Aβ accumulation. This study supports the potential use of this panel of CSF Aβ peptides to indicate presence of CAA pathology with high accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy.
- Author
-
Jäkel, Lieke, De Kort, Anna M., Stellingwerf, Arno, Hernández Utrilla, Carla, Kersten, Iris, Vervuurt, Marc, Vermeiren, Yannick, Küsters, Benno, Schreuder, Floris H. B. M., Klijn, Catharina J. M., Kuiperij, H. Bea, and Verbeek, Marcel M.
- Subjects
CEREBRAL amyloid angiopathy ,MOLECULAR pathology ,CEREBROSPINAL fluid ,TISSUE inhibitors of metalloproteinases ,VASCULAR dementia ,CEREBROSPINAL fluid examination ,CEREBRAL hemorrhage - Abstract
Cerebral amyloid angiopathy (CAA) is a highly prevalent and progressive pathology, involving amyloid-β (Aβ) deposition in the cerebral blood vessel walls. CAA is associated with an increased risk for intracerebral hemorrhages (ICH). Insight into the molecular mechanisms associated with CAA pathology is urgently needed, to develop additional diagnostic tools to allow for reliable and early diagnosis of CAA and to obtain novel leads for the development of targeted therapies. Tissue inhibitor of matrix metalloproteinases 4 (TIMP4) is associated with cardiovascular functioning and disease and has been linked to vascular dementia. Using immunohistochemistry, we studied occipital brain tissue samples of 57 patients with CAA (39 without ICH and 18 with ICH) and 42 controls, and semi-quantitatively assessed expression levels of TIMP4. Patients with CAA had increased vascular expression of TIMP4 compared to controls (p < 0.001), and in these patients, TIMP4 expression correlated with CAA severity (τ
b = 0.38; p = 0.001). Moreover, TIMP4 expression was higher in CAA-ICH compared to CAA-non-ICH cases (p = 0.024). In a prospective cross-sectional study of 38 patients with CAA and 37 age- and sex-matched controls, we measured TIMP4 levels in cerebrospinal fluid (CSF) and serum using ELISA. Mean CSF levels of TIMP4 were decreased in patients with CAA compared to controls (3.36 ± 0.20 vs. 3.96 ± 0.22 ng/ml, p = 0.033), whereas median serum levels were increased in patients with CAA (4.51 ng/ml [IQR 3.75–5.29] vs 3.60 ng/ml [IQR 3.11–4.85], p-9.013). Moreover, mean CSF TIMP4 levels were lower in CAA patients who had experienced a symptomatic hemorrhage compared to CAA patients who did not (2.13 ± 0.24 vs. 3.57 ± 0.24 ng/ml, p = 0.007). CSF TIMP4 levels were associated with CSF levels of Aβ40 (spearman r (rs ) = 0.321, p = 0.009). In summary, we show that TIMP4 is highly associated with CAA and CAA-related ICH, which is reflected by higher levels in the cerebral vasculature and lower levels in CSF. With these findings we provide novel insights into the pathophysiology of CAA, and more specifically in CAA-associated ICH. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
9. Translational validation of shotgun proteomics findings in cerebrospinal fluid of sporadic cerebral amyloid angiopathy patients
- Author
-
Vervuurt, Marc, primary, de Kort, Anna M., additional, Kersten, Iris, additional, Rens, Astrid van, additional, Klijn, Catharina J. M., additional, Schreuder, Floris H. B. M., additional, Lefeber, Dirk J., additional, Kuiperij, H. Bea, additional, and Verbeek, Marcel M., additional
- Published
- 2024
- Full Text
- View/download PDF
10. Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients
- Author
-
Vervuurt, Marc, primary, Schrader, Joseph M., additional, de Kort, Anna M., additional, Kersten, Iris, additional, Wessels, Hans J. C. T., additional, Klijn, Catharina J. M., additional, Schreuder, Floris H. B. M., additional, Kuiperij, H. Bea, additional, Gloerich, Jolein, additional, Van Nostrand, William E., additional, and Verbeek, Marcel M., additional
- Published
- 2024
- Full Text
- View/download PDF
11. The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.
- Author
-
De Kort, Anna M., Kaushik, Kanishk, Kuiperij, H. Bea, Jäkel, Lieke, Li, Hao, Tuladhar, Anil M., Terwindt, Gisela M., Wermer, Marieke J. H., Claassen, Jurgen A. H. R., Klijn, Catharina J. M., Verbeek, Marcel M., Kessels, Roy P. C., and Schreuder, Floris H. B. M.
- Subjects
VERBAL behavior testing ,CEREBRAL amyloid angiopathy ,ALZHEIMER'S disease ,COGNITIVE ability ,CEREBROSPINAL fluid ,EPISODIC memory ,EXECUTIVE function ,APATHY - Abstract
Background: Patients with sporadic cerebral amyloid angiopathy (sCAA) frequently report cognitive or neuropsychiatric symptoms. The aim of this study is to investigate whether in patients with sCAA, cognitive impairment and neuropsychiatric symptoms are associated with a cerebrospinal fluid (CSF) biomarker profile associated with Alzheimer's disease (AD). Methods: In this cross-sectional study, we included participants with sCAA and dementia- and stroke-free, age- and sex-matched controls, who underwent a lumbar puncture, brain MRI, cognitive assessments, and self-administered and informant-based-questionnaires on neuropsychiatric symptoms. CSF phosphorylated tau, total tau and Aβ42 levels were used to divide sCAA patients in two groups: CAA with (CAA-AD+) or without a CSF biomarker profile associated with AD (CAA-AD-). Performance on global cognition, specific cognitive domains (episodic memory, working memory, processing speed, verbal fluency, visuoconstruction, and executive functioning), presence and severity of neuropsychiatric symptoms, were compared between groups. Results: sCAA-AD+ (n=31; mean age: 72 ± 6; 42%, 61% female) and sCAA-AD- (n=23; 70 ± 5; 42% female) participants did not differ with respect to global cognition or type of affected cognitive domain(s). The number or severity of neuropsychiatric symptoms also did not differ between sCAA-AD+ and sCAA-AD- participants. These results did not change after exclusion of patients without prior ICH. Conclusions: In participants with sCAA, a CSF biomarker profile associated with AD does not impact global cognition or specific cognitive domains, or the presence of neuropsychiatric symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective.
- Author
-
Peters, Tessa M. A., Engelke, Udo F. H., de Boer, Siebolt, Reintjes, Joris T. G., Roullet, Jean‐Baptiste, Broekman, Sanne, de Vrieze, Erik, van Wijk, Erwin, Wamelink, Mirjam M. C., Artuch, Rafael, Barić, Ivo, Merx, Jona, Boltje, Thomas J., Martens, Jonathan, Willemsen, Michèl A. A. P., Verbeek, Marcel M., Wevers, Ron A., Gibson, K. Michael, and Coene, Karlien L. M.
- Abstract
Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare neurometabolic disorder caused by disruption of the gamma‐aminobutyric acid (GABA) pathway. A more detailed understanding of its pathophysiology, beyond the accumulation of GABA and gamma‐hydroxybutyric acid (GHB), will increase our understanding of the disease and may support novel therapy development. To this end, we compared biochemical body fluid profiles from SSADHD patients with controls using next‐generation metabolic screening (NGMS). Targeted analysis of NGMS data from cerebrospinal fluid (CSF) showed a moderate increase of aspartic acid, glutaric acid, glycolic acid, 4‐guanidinobutanoic acid, and 2‐hydroxyglutaric acid, and prominent elevations of GHB and 4,5‐dihydroxyhexanoic acid (4,5‐DHHA) in SSADHD samples. Remarkably, the intensities of 4,5‐DHHA and GHB showed a significant positive correlation in control CSF, but not in patient CSF. In an established zebrafish epilepsy model, 4,5‐DHHA showed increased mobility that may reflect limited epileptogenesis. Using untargeted metabolomics, we identified 12 features in CSF with high biomarker potential. These had comparable increased fold changes as GHB and 4,5‐DHHA. For 10 of these features, a similar increase was found in plasma, urine and/or mouse brain tissue for SSADHD compared to controls. One of these was identified as the novel biomarker 4,5‐dihydroxyheptanoic acid. The intensities of selected features in plasma and urine of SSADHD patients positively correlated with the clinical severity score of epilepsy and psychiatric symptoms of those patients, and also showed a high mutual correlation. Our findings provide new insights into the (neuro)metabolic disturbances in SSADHD and give leads for further research concerning SSADHD pathophysiology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathy.
- Author
-
Kaushik, Kanishk, de Kort, Anna M., van Dort, Rosemarie, van der Zwet, Reinier G.J., Siegerink, Bob, Voigt, Sabine, van Zwet, Erik W., van der Plas, Maaike C., Koemans, Emma A., Rasing, Ingeborg, Kessels, Roy P.C., Middelkoop, Huub A.M., Schreuder, Floris H.B.M., Klijn, Catharina J.M., Verbeek, Marcel M., Terwindt, Gisela M., van Etten, Ellis S., and Wermer, Marieke J.H.
- Subjects
CEREBRAL amyloid angiopathy ,COGNITIVE processing speed ,APATHY ,EXECUTIVE function ,CEREBRAL hemorrhage - Abstract
Background: Neuropsychiatric symptoms (NPS) may affect cognition, but their burden in cerebral amyloid angiopathy (CAA), one of the main causes of intracerebral hemorrhage (ICH) and dementia in the elderly, remains unclear. We investigated NPS, with emphasis on apathy and irritability in sporadic (sCAA) and Dutch-type hereditary (D-)CAA. Methods: We included patients with sCAA and (pre)symptomatic D-CAA, and controls from four prospective cohort studies. We assessed NPS per group, stratified for history of ICH, using the informant-based Neuropsychiatric Inventory (NPI-Q), Starkstein Apathy scale (SAS), and Irritability Scale. We modeled the association of NPS with disease status, executive function, processing speed, and CAA-burden score on MRI and investigated sex-differences. Results: We included 181 participants: 82 with sCAA (mean[SD] age 72[6] years, 44% women, 28% previous ICH), 56 with D-CAA (52[11] years, 54% women, n = 31[55%] presymptomatic), and 43 controls (69[9] years, 44% women). The NPI-Q NPS-count differed between patients and controls (sCAA-ICH+:adj.β = 1.4[95%CI:0.6–2.3]; sCAA-ICH-:1.3[0.6-2.0]; symptomatic D-CAA:2.0[1.1–2.9]; presymptomatic D-CAA:1.2[0.1–2.2], control median:0[IQR:0–3]), but not between the different CAA-subgroups. Apathy and irritability were reported most frequently: n = 12[31%] sCAA, 19[37%] D-CAA had a high SAS-score; n = 12[29%] sCAA, 14[27%] D-CAA had a high Irritability Scale score. NPS-count was associated with decreased processing speed (adj.β=-0.6[95%CI:-0.8;-0.4]) and executive function (adj.β=-0.4[95%CI:-0.6;-0.1]), but not with radiological CAA-burden. Men had NPS more often than women. Discussion: According to informants, one third to half of patients with CAA have NPS, mostly apathy, even in presymptomatic D-CAA and possibly with increased susceptibility in men. Neurologists should inform patients and caregivers of these disease consequences and treat or refer patients with NPS appropriately. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Correction: Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid angiopathy.
- Author
-
Rasing, Ingeborg, Voigt, Sabine, Koemans, Emma A., de Kort, Anna M., van Harten, Thijs W., van Etten, Ellis S., van Zwet, Erik W., Stoops, Erik, Francois, Cindy, Kuiperij, H. Bea, Klijn, Catharina J.M., Schreuder, Floris H.B.M., van der Weerd, Louise, van Osch, Matthias J.P., van Walderveen, Marianne A.A., Verbeek, Marcel M., Terwindt, Gisela M., and Wermer, Marieke J.H.
- Subjects
CEREBRAL amyloid angiopathy ,CEREBROSPINAL fluid ,CYTOPLASMIC filaments ,PROTEINS - Abstract
This correction notice is from the journal Alzheimer's Research & Therapy and addresses inaccuracies in an original article. The correction includes the addition of a funding statement for Sabine Voigt and a correction to the name of the tenth co-author. The original article has been corrected. The publisher, Springer Nature, remains neutral in regards to jurisdictional claims and institutional affiliations. The authors of the original article are listed at the end of the correction notice. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
15. Multimodal, Longitudinal Profiling of SCA1 Identifies Predictors of Disease Severity and Progression.
- Author
-
Prooije, Teije H., Kapteijns, Kirsten C.J., Asten, Jack J.A., IntHout, Joanna, Verbeek, Marcel M., Scheenen, Tom W.J., and Warrenburg, Bart P.
- Subjects
- *
GLIAL fibrillary acidic protein , *WHITE matter (Nerve tissue) , *DISEASE duration , *CEREBROSPINAL fluid , *DISEASE progression , *SPINOCEREBELLAR ataxia , *CEREBELLUM degeneration - Abstract
Objectives Methods Results Interpretation Spinocerebellar ataxia type 1 (SCA1) is a rare autosomal dominant neurodegenerative disease. Objective surrogate markers sensitive to detect changes in disease severity are needed to reduce sample sizes in interventional trials and identification of predictors of faster disease progression would facilitate patient selection, enrichment, or stratification in such trials.We performed a prospective 1‐year longitudinal, multimodal study in 34 ataxic SCA1 individuals and 21 healthy controls. We collected clinical, patient‐reported outcomes, biochemical and magnetic resonance (MR) biomarkers at baseline and after 1 year. We determined 1‐year progression and evaluated the potential predictive value of several baseline markers on 1‐year disease progression.At baseline, multiple structural and spectroscopic MR markers in pons and cerebellum differentiated SCA1 from healthy controls and correlated with disease severity. Plasma and cerebrospinal fluid (CSF) neurofilament light (NfL) chain and CSF glial fibrillary acidic protein (GFAP) were elevated in SCA1. In longitudinal analysis, total brainstem and pontine volume change, inventory of non‐ataxia signs (INAS) count, and SCA functional index (SCAFI) showed larger responsiveness compared to the Scale for Assessment and Rating of Ataxia (SARA).Longer disease duration, longer non‐expanded CAG repeat length, and higher disease burden were associated with faster SARA increase after 1‐year in the SCA1 group. Similarly, lower baseline brainstem, pontine, and cerebellar volumes, as well as lower levels of N‐acetylaspartate and glutamate in the cerebellar white matter, were also associated with faster SARA increase.Our results guide the selection of the most sensitive measures of disease progression in SCA1 and have identified features associated with accelerated progression that could inform the design of clinical trials. ANN NEUROL 2024 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Decreased microvascular claudin‐5 levels in cerebral amyloid angiopathy associated with intracerebral haemorrhage.
- Author
-
Jäkel, Lieke, Claassen, Kiki K. W. J., De Kort, Anna M., Jolink, Wilmar M. T., Vermeiren, Yannick, Schreuder, Floris H. B. M., Küsters, Benno, Klijn, Catharina J. M., Kuiperij, H. Bea, and Verbeek, Marcel M.
- Published
- 2024
- Full Text
- View/download PDF
17. Multimodal, Longitudinal Profiling of SCA1 Identifies Predictors of Disease Severity and Progression.
- Author
-
van Prooije TH, Kapteijns KCJ, van Asten JJA, IntHout J, Verbeek MM, Scheenen TWJ, and van de Warrenburg BP
- Abstract
Objectives: Spinocerebellar ataxia type 1 (SCA1) is a rare autosomal dominant neurodegenerative disease. Objective surrogate markers sensitive to detect changes in disease severity are needed to reduce sample sizes in interventional trials and identification of predictors of faster disease progression would facilitate patient selection, enrichment, or stratification in such trials., Methods: We performed a prospective 1-year longitudinal, multimodal study in 34 ataxic SCA1 individuals and 21 healthy controls. We collected clinical, patient-reported outcomes, biochemical and magnetic resonance (MR) biomarkers at baseline and after 1 year. We determined 1-year progression and evaluated the potential predictive value of several baseline markers on 1-year disease progression., Results: At baseline, multiple structural and spectroscopic MR markers in pons and cerebellum differentiated SCA1 from healthy controls and correlated with disease severity. Plasma and cerebrospinal fluid (CSF) neurofilament light (NfL) chain and CSF glial fibrillary acidic protein (GFAP) were elevated in SCA1. In longitudinal analysis, total brainstem and pontine volume change, inventory of non-ataxia signs (INAS) count, and SCA functional index (SCAFI) showed larger responsiveness compared to the Scale for Assessment and Rating of Ataxia (SARA). Longer disease duration, longer non-expanded CAG repeat length, and higher disease burden were associated with faster SARA increase after 1-year in the SCA1 group. Similarly, lower baseline brainstem, pontine, and cerebellar volumes, as well as lower levels of N-acetylaspartate and glutamate in the cerebellar white matter, were also associated with faster SARA increase., Interpretation: Our results guide the selection of the most sensitive measures of disease progression in SCA1 and have identified features associated with accelerated progression that could inform the design of clinical trials. ANN NEUROL 2024., (© 2024 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
- Published
- 2024
- Full Text
- View/download PDF
18. Prevalence of Cerebral Amyloid Angiopathy Pathology and Strictly Lobar Microbleeds in East-Asian Versus Western Populations: A Systematic Review and Meta-Analysis.
- Author
-
De Kort AM, Verbeek MM, Schreuder FHBM, Klijn CJM, and Jäkel L
- Abstract
Background and Purpose: Possible differences in the prevalence of cerebral amyloid angiopathy (CAA) in East-Asian compared to Western populations have received little attention, and results so far have been ambiguous. Our aim is to compare the prevalence of CAA neuropathology and magnetic resonance imaging markers of CAA in East-Asian and Western cohorts reflecting the general population, cognitively normal elderly, patients with Alzheimer's disease (AD), and patients with (lobar) intracerebral hemorrhage (ICH)., Methods: We performed a systematic literature search in PubMed and Embase for original research papers on the prevalence of CAA and imaging markers of CAA published up until February 17th 2022. Records were screened by two independent reviewers. Pooled estimates were determined using random-effects models. We compared studies from Japan, China, Taiwan, South Korea (East-Asian cohorts) to studies from Europe or North America (Western cohorts) by meta-regression models., Results: We identified 12,257 unique records, and we included 143 studies on Western study populations and 53 studies on East-Asian study populations. Prevalence of CAA neuropathology did not differ between East-Asian and Western cohorts in any of the investigated patient domains. The prevalence of strictly lobar microbleeds was lower in East-Asian cohorts of population-based individuals (5.6% vs. 11.4%, P=0.020), cognitively normal elderly (2.6% vs. 11.4%, P=0.001), and patients with ICH (10.2% vs. 24.6%, P<0.0001). However, age was in general lower in the East-Asian cohorts., Conclusion: The prevalence of CAA neuropathology in the general population, cognitively normal elderly, patients with AD, and patients with (lobar) ICH is similar in East-Asian and Western countries. In East-Asian cohorts reflecting the general population, cognitively normal elderly, and patients with ICH, strictly lobar microbleeds were less prevalent, likely due to their younger age. Consideration of potential presence of CAA is warranted in decisions regarding antithrombotic treatment and potential new anti-amyloid-β immunotherapy as treatment for AD in East-Asian and Western countries alike.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.